Tarek M. Mekhail, MD

Tarek M. Mekhail, MD

Medical Director (Thoracic Cancer), Medical Oncologist

Cancer

Tarek Mekhail

Overview

Dr. Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd is board-certified in internal medicine, hematology and oncology. Dr. Mekhail serves as medical director of the Thoracic Cancer Program at the Florida Hospital Cancer Institute. He joined the team from the Cleveland Clinic where he was the director of the Lung Cancer Medical Oncology Program. Dr. Mekhail completed his medical degree at Cairo University in 1988, then went on to complete his medical training in the United Kingdom, where he earned fellowships of the Royal College of Surgeon of Edinburgh and Ireland. He completed his medical oncology fellowship at the Cleveland Clinic in Cleveland, Ohio. He is an associate professor at the University of Central Florida. Dr. Mekhail's extensive experience in the field of lung cancer is bolstered by his many awards, including being voted one of the Best Doctors in America in 2007-2008, 2008-2009 and 2009-2010.

Articles

Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort

JOURNAL OF CLINICAL MEDICINE

2023

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

NATURE MEDICINE

2022

Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer

Expert review of anticancer therapy

2022

GEMSTONE-302: "If you keep doing the same thing you get the same result"

CHINESE CLINICAL ONCOLOGY

2022

Langerhans Cell Histiocytosis Associated With Renal Cell Carcinoma Is it an Indolent Phenomenon or a More Ominous Pathologic Process?

AMERICAN JOURNAL OF SURGICAL PATHOLOGY

2022

A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors

JOURNAL OF IMMUNOTHERAPY

2022

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer A Phase 1/2 Open-label Nonrandomized Clinical Trial

JAMA ONCOLOGY

2021

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

CANCER DISCOVERY

2021

Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors

ANNALS OF ONCOLOGY

2021

Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy

ANNALS OF ONCOLOGY

2021

More Publication Information

Education & Training

Education

Cairo University Egypt

Residency

Cleveland Clinic Foundation Ohio

Fellowship

Cleveland Clinic Foundation Ohio

Specialty

Medical Oncology

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT02367781

A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDl3280A (Anti−PD-L1 Antibody) In Combination with Carboplatin and Nab-Paclitaxel for Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non−Small Cell Lung Cancer

Icon for trial | GO29537 A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDl3280A (Anti−PD-L1 Antibody) In Combination with Carboplatin and Nab-Paclitaxel for Chemotherapy-Naïve Patients with Stage IV Non-Squamous N

This study is currently enrolling.

[Abbreviated - Closed] The purpose of this study is to look at the effects, good or bad, of MPDL3280A on you and the specific type of lung cancer (non−small cell lung cancer [NSCLC]) from which you are suffering. MPDL3280A is a ...

NCT05211895

D9075C00001: A Phase 3, Randomized, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab and Domvanalimab (AB154) as Sequential Therapy in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive, Platinum-based Concurrent Chemoradiation Therapy (PACIFIC 8)

Icon for trial | D9705C00001 D9075C00001: A Phase 3, Randomized, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab and Domvanalimab (AB154) as Sequential Therapy in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell

This study is currently enrolling.

This study is being carried out in stage III NSCLC which cannot be removed by surgery. In this study, we will identify the effectiveness and safety of a possible treatment combination – durvalumab with domvanalimab, comparing t ...

NCT05364073

FURMO-002: A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Activating EGFR or HER2 Mutations, Including Exon 20 Insertion Mutations

Icon for trial | FURMO-002 FURMO-002: A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Activating EGFR or HE

This study is currently enrolling.

The purpose of this study is to learn about how the study drug, furmonertinib, works in patients with NSCLC who have a mutation in the EGFR or HER2 gene and how it may help them. For patients with this type of NSCLC, the study ...

NCT05450692

AstraZeneca AB / “A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY”

Icon for trial | D533BC00001 AstraZeneca AB / “A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whos

This study is currently enrolling.

We are doing this study to learn more about the effect of Ceralasertib plus Durvalumab on the inhibition of tumor growth, and also to better understand the studied disease and associated

NCT05353257

Shanghai Henlius Biotech, Inc. / “A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)”

Icon for trial | HLX10-020-SCLC302 Shanghai Henlius Biotech, Inc. / “A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Pla

This study is currently enrolling.

The purpose of this study is to compare the efficacy of the investigational drug and placebo (an inactive substance) in combination with chemotherapy and concurrent radiotherapy in your disease and collect safety information on ...